Activation of cdk4/Cyclind D1 and the Associated Attenuation of Rb Function in Pancreatic Neuroendocrine Tumors (Pan-NETs) Abstract #409

Introduction: Pan-NET poses challenges in clinical management due to the lack of identifications of key oncogenic pathways in this neoplasm. There are no reliable biomarkers to predict the recurrence and progression and treatment option is limited. Genetic changes in Rb pathway can lead to Pan-NET formation in mice. Genomic investigations in humans have not revealed Rb pathway mutation.
Aim(s): To investigate abnormalities in the Rb pathway in Pan-NETs.
Materials and methods: IHC was carried out on tissue microarray of Pan-NET. qRT-PCR was performed using mRNA from fresh samples of Pan-NETs. Gene maplification was performed by PCR and by FISH. Compound PD 0332991, a specific cdk4/6 inhibitor, was tested in Pan-NET cell lines.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Laura Tang
Authors: Tang L

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1688 Pancreatic NET-G3 Does Not Respond to Platinum-Based Chemotherapy: A Multicenter Study of Neuroendocrine Carcinomas
Introduction: Recent studies have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Ph.D. Susumu Hijioka
Authors: Hijioka S, Hosoda W, Matsuo K, Ueno M, ...
Keywords: NET G3, NEC, KRAS, Rb
#67 Interest of combined chromogranin A and pancreatic polypeptide for diagnosis and follow-up of gastroenteropancreatic endocrine carcinoma
Introduction: Assessment of tumor burden changes is essential for the management of well-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEPNET). Chromogranin A (CgA) is the principal tumor marker for such tumors; however, its use to evaluate morphological tumor progression is not validated. Combined CgA and pancreatic polypeptide (PP) may increase sensitivity in the diagnosis of GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Thomas WALTER
#1493 Efficacy and Tolerance of a Simplified Combination of Streptozotocine and Epi-adriamycine in Metastatic Foregut Neuroendocrine Tumor (NET). A Pilot Study
Introduction: Since more than 30 years the combination of Adriamycine (A) and Streptozotocine (STZ) is considered as one of the standard chemotherapy regimens (Moertel et al, N Engl J Med 1992, 326 : 519-23) for patients with aggressive grade 2 metastatic pancreatic NET (PNET).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Celine Lepère
Authors: Hirsch L, Lepère C, Zaanan A, Landi B, ...
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#1253 A Novel Hereditary Pancreatic Neuroendocrine Tumor Syndrome Associated with Biallelic Inactivation of the Glucagon Receptor
Introduction: Hereditary pancreatic neuroendocrine tumors (PanNETs) are associated with 4 known autosomal dominant syndromes including MEN1, vHL disease, NF1, and TS. Glucagon receptor (GCGR) inactivation in human (Mahvash disease) has been associated with asymptomatic hyperglucagonemia, α-cell hyperplasia, and PanNET, and may represent a new hereditary syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr. Laura Tang
Authors: Tang L, Yu R, ...
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.